Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isconova, an international vaccine adjuvant company, has started vaccination in a Phase I trial to assess Matrix M as a treatment for seasonal influenza.
Subscribe to our email newsletter
The company expects to enroll around 110 healthy subjects.
The study expects to evaluate whether Matrix M is safe and improves the effect on elderly people, due to a weakened immune system.
Isconova’s Phase I trial of seasonal influenza is initiated on the basis of the positive results from a prior study which evaluated Matrix M against avian influenza.
Isconova CEO Lena Soderstrom said the initiation of the clinical study in humans is an important milestone towards establishing Isconova in the growing human vaccine market.
"There is a medical need for better and more effective vaccines – including for seasonal influenza – and our expectation is that Matrix M can address this need in a number of future vaccines," Soderstrom said.